Skip to Content

The clinical value of circulating tumor DNA in renal cancer

Circulating tumor DNA, ctDNA, has the potential to be used throughout the disease course from cancer detection, molecular profiling or prognostication, detection of residual disease, monitoring response, and monitoring clonal evolution. In this MEDtalk, Lars Dyrskjøt, Ph.D., professor, Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark, presents an update about the latest results of ctDNA in renal cancer – an update he also presented at ESMO 2022 Congress. As you will hear, according to Lars Dyrskjøt, ctDNA in renal cancer needs to be investigated further to determine clinical value.

Lars Dyrskjøt Andersen

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top